One anti-TIGIT antibody, tiragolumab, showed promising activity in NSCLC in a randomized phase II placebo-controlled trial of tiragolumab with atezolizumab vs. atezolizumab alone in the first line treatment of EGFR/ALK wildtype NSCLC patients who were PD-L1 TPS positive [139]. Here, ALK is linked to non-small cell lung carcinoma.